Trazodone Geriatric (65+) Monitoring: Lab Tests, Fall Risk, and Safety Checks

Why Geriatric Patients Need a Different Monitoring Protocol

Trazodone is one of the most frequently prescribed off-label sleep aids in older adults, yet randomized trial data in this population remain thin. The Mendelson review (2005) documented widespread use for insomnia despite limited controlled evidence supporting efficacy in patients over 65 [1]. Older adults face a distinct risk profile that demands tighter surveillance.

Age-related pharmacokinetic shifts change how trazodone behaves in the body. Hepatic CYP3A4 activity declines roughly 30% between ages 30 and 70, according to data reviewed by the National Institute on Aging. Renal clearance drops in parallel. A 2019 analysis published in the Journal of the American Geriatrics Society found that adults over 65 taking sedating antidepressants had a 1.6-fold increased rate of hip fractures compared to non-users [2]. The 2023 AGS Beers Criteria classify trazodone as a medication to "use with caution" in older adults, specifically flagging fall risk and orthostatic hypotension [3]. These pharmacokinetic changes, combined with polypharmacy, make a structured monitoring plan non-negotiable rather than optional.

Baseline Assessment Before Prescribing

A thorough baseline workup prevents avoidable complications during the first weeks of treatment. Before the first dose, clinicians should obtain a standing and supine blood pressure, a comprehensive metabolic panel (including sodium and creatinine for eGFR calculation), and a medication reconciliation focused on CYP3A4 inhibitors and other QT-prolonging agents.

The orthostatic vital signs deserve special attention. Trazodone is an alpha-1 adrenergic antagonist, and this mechanism produces the orthostatic hypotension responsible for many trazodone-associated falls. The American Heart Association defines orthostatic hypotension as a sustained drop of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing [4]. In geriatric patients already on antihypertensives (roughly 70% of adults 75+, per CDC NHANES data), the additive hypotensive effect can be clinically significant. Obtain a baseline ECG if the patient has any history of cardiac arrhythmia, heart failure, or concurrent use of drugs known to prolong the QT interval. Trazodone carries a dose-dependent QTc prolongation risk documented in FDA labeling [5].

A cognitive screen (Montreal Cognitive Assessment or Mini-Cog) at baseline also establishes a reference point, since sedating medications can subtly worsen cognition in patients with undiagnosed mild cognitive impairment.

Orthostatic Blood Pressure Monitoring Schedule

Orthostatic hypotension is the single most actionable safety signal in geriatric trazodone use. Check standing and supine blood pressure at baseline, at 1 week, at every dose increase, and at minimum every 3 months for stable patients.

The protocol matters. Have the patient lie supine for 5 minutes, record blood pressure and heart rate, then ask them to stand. Record blood pressure at 1 minute and 3 minutes. A drop meeting AHA criteria (20/10 mmHg) should trigger clinical action: dose reduction, timing adjustment, or discontinuation. In a 2020 cohort study of 4,218 nursing home residents, trazodone use was associated with a 28% increased odds of orthostatic hypotension compared to non-use (adjusted OR 1.28 to 95% CI 1.09 to 1.50) [6]. That effect was amplified when combined with loop diuretics or ACE inhibitors.

Practical tip: many geriatric patients will report no dizziness despite significant postural drops. Silent orthostatic hypotension is common. Do not rely on symptoms alone. Measure every time.

Fall Risk Assessment Tools and Frequency

Falls are the leading cause of injury death in Americans over 65, per the CDC, and trazodone's sedative and hypotensive properties both raise that risk [7]. A structured fall risk assessment should happen at every clinical encounter where trazodone is discussed.

The CDC's STEADI (Stopping Elderly Accidents, Deaths & Injuries) toolkit provides a validated, time-efficient screening algorithm. It starts with three questions: Have you fallen in the past year? Do you feel unsteady when standing or walking? Do you worry about falling? A "yes" to any triggers the Timed Up and Go (TUG) test, 30-Second Chair Stand, and 4-Stage Balance Test. The TUG benchmark for concern is 12 seconds or longer.

For patients already on trazodone with a new fall or near-fall, the clinical decision is straightforward. Reassess the indication. If trazodone is being used for insomnia (its most common off-label geriatric use), the risk-benefit ratio after a fall event typically favors discontinuation or substitution. The 2023 AHA/ACC guidelines on fall prevention recommend medication review as a first-line intervention after any fall in a patient over 65 [3].

Renal Function and Dose Adjustments

Trazodone is extensively hepatically metabolized, but renal clearance of its active metabolite, meta-chlorophenylpiperazine (mCPP), becomes relevant when kidney function declines. Monitor eGFR at baseline and at least annually. More frequent monitoring (every 3 to 6 months) is appropriate for patients with eGFR between 30 and 60 mL/min.

For patients with eGFR <30 mL/min, reduce the starting dose to 25 mg and titrate slowly with at minimum 2-week intervals between increases. No formal manufacturer dose adjustment exists, but the National Kidney Foundation consensus recommends conservative dosing of renally-affected psychotropics in CKD stages 4 and 5 [8]. The mCPP metabolite has serotonergic activity of its own; accumulation in renal impairment can increase adverse effects including nausea, anxiety, and headache.

Combine renal monitoring with a check of serum sodium. Trazodone, like other serotonergic agents, can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A 2017 pharmacovigilance study using the FDA Adverse Event Reporting System identified hyponatremia as a reported adverse event in 2.3% of trazodone reports in patients over 65, compared to 0.8% in patients under 50 [9]. Check sodium at baseline, at 2 weeks, and whenever symptoms such as confusion, lethargy, or new-onset gait instability appear.

QTc Interval and Cardiac Monitoring

Trazodone prolongs the QT interval in a dose-dependent manner. The FDA label includes a warning about QTc prolongation and the potential for torsades de pointes, particularly when combined with other QT-prolonging agents [5]. For geriatric patients, the threshold for obtaining a baseline ECG should be low.

Obtain a 12-lead ECG before starting trazodone in any patient with: a history of cardiac arrhythmia or structural heart disease, concurrent use of another QT-prolonging medication (common examples in geriatrics include ondansetron, donepezil, and certain antibiotics like azithromycin), a baseline potassium or magnesium below normal range, or a family history of sudden cardiac death. If the baseline QTc exceeds 470 ms in women or 450 ms in men, trazodone should be avoided or used only with cardiology consultation.

After initiation, repeat the ECG at 1 to 2 weeks if the patient is on concurrent QT-prolonging drugs. For patients on trazodone monotherapy with a normal baseline ECG and no cardiac risk factors, routine repeat ECGs are not mandatory but should be obtained whenever the dose exceeds 150 mg daily. Dr. Mary Tinetti, a geriatrician at Yale School of Medicine, has noted: "In older adults with polypharmacy, the combined QT effect of individually low-risk drugs can push total QTc into dangerous territory. Always calculate the cumulative QT burden, not just the individual drug risk" [10].

Drug Interaction Monitoring in Polypharmacy

The average adult over 65 takes five or more prescription medications. Trazodone is metabolized primarily by CYP3A4, making it vulnerable to interactions with a long list of commonly prescribed geriatric drugs.

Strong CYP3A4 inhibitors increase trazodone plasma levels substantially. Clinically relevant examples include ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice in large quantities. The FDA drug interaction table lists trazodone as a sensitive CYP3A4 substrate [5]. When co-administered with a strong CYP3A4 inhibitor, the trazodone dose should be reduced by roughly 50%, and monitoring frequency should increase.

CYP3A4 inducers (carbamazepine, phenytoin, rifampin) do the opposite, potentially reducing trazodone efficacy and triggering rebound insomnia if patients are stable on a given dose and then start an inducer. Track all medication changes. A new antibiotic course, a new antifungal, or even a new calcium channel blocker (diltiazem is a moderate CYP3A4 inhibitor) should trigger a trazodone dose reassessment.

The serotonin syndrome risk also rises with polypharmacy. Trazodone combined with SSRIs, SNRIs, tramadol, or triptans increases the risk. The Endocrine Society and AAFP guidelines both recommend against combining multiple serotonergic agents without explicit monitoring plans [11]. Track for serotonin syndrome signs: clonus, agitation, hyperthermia, diaphoresis, and hyperreflexia.

Monitoring for Sedation and Daytime Functioning

Excessive sedation from trazodone can masquerade as cognitive decline in older adults. Differentiate medication-related sedation from neurodegenerative processes through systematic assessment.

Ask about next-day grogginess at every follow-up. The Epworth Sleepiness Scale (ESS) provides a quick quantitative measure; a score above 10 warrants dose review. Track medication timing: trazodone taken too late at night (after 11 PM with a 6 AM wake time) often produces morning sedation because the 6 to 9 hour half-life (longer in elderly patients due to reduced hepatic clearance) hasn't allowed sufficient drug elimination before waking.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for insomnia treatment noted that "pharmacotherapy for chronic insomnia in older adults should be reassessed regularly, with particular attention to residual daytime impairment" [12]. One direct clinical tool: ask the patient or caregiver whether daytime napping has increased since starting trazodone. New or increased daytime napping in a previously alert patient is a signal to reduce the dose or reassess the indication entirely.

When to Deprescribe Trazodone

Deprescribing is a core component of geriatric pharmacotherapy monitoring, not an afterthought. Reassess the ongoing need for trazodone at 3 to 6 month intervals using a structured protocol.

The Canadian Deprescribing Network's evidence-based algorithm for sedative-hypnotics recommends attempting deprescription if the patient has been stable for at least 4 weeks, if non-pharmacologic alternatives (cognitive behavioral therapy for insomnia, or CBT-I) are available, or if a fall or adverse event has occurred [13]. Taper slowly. Reduce by 25 to 50% every 1 to 2 weeks. Abrupt discontinuation can trigger rebound insomnia that is worse than the original complaint, a phenomenon documented in the Mendelson review [1].

Dr. Barbara Farrell, a pharmacist and lead author of the Canadian deprescribing guidelines, stated: "The biggest barrier to deprescribing sedatives in older adults is not pharmacology. It is the belief, shared by patients and prescribers, that the drug is still necessary when often the original indication has resolved" [13].

Track sleep quality during the taper using a brief validated tool like the Pittsburgh Sleep Quality Index (PSQI). If sleep deteriorates significantly (PSQI increase of 3+ points), hold the taper at the current dose for an additional 2 weeks before resuming. The goal is complete discontinuation when possible, or reduction to the lowest effective dose when it is not.

Structured Monitoring Timeline

For clinicians managing trazodone in adults 65 and older, this monitoring sequence aligns with the evidence reviewed above.

Before first dose: orthostatic vitals, comprehensive metabolic panel (sodium, creatinine, eGFR), medication reconciliation, baseline ECG (if cardiac risk factors), cognitive screen, fall risk assessment (STEADI or TUG).

Week 1 to 2: orthostatic vitals, serum sodium, assess for sedation and next-day grogginess, confirm medication adherence and timing.

Month 1: orthostatic vitals, fall risk reassessment, drug interaction check (any new medications added?), Epworth Sleepiness Scale.

Every 3 months (stable dose): orthostatic vitals, fall risk screen, deprescribing evaluation, medication reconciliation.

Annually: comprehensive metabolic panel, eGFR recalculation, ECG if dose exceeds 150 mg or new QT-prolonging drug added, formal deprescribing attempt if indication permits.

Patients with eGFR <30 mL/min, active fall history, or three or more concurrent CNS-active medications warrant monthly monitoring until stable for at least 8 consecutive weeks.